Not imagining it. Research into hallucinogens cautiously resumes.
Biello
David
D
D018849:Controlled Clinical Trials as Topic; D004311:Double-Blind Method; D006213:Hallucinogens / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D009228:Mysticism; D004130:N,N-Dimethyltryptamine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000009:adverse effects / Q000494:pharmacology; D011562:Psilocybin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D012106:Research; D029181:Spirituality
D006213:Hallucinogens; D011562:Psilocybin; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D004130:N,N-Dimethyltryptamine